Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04LWO
|
||||
| Former ID |
DIB010579
|
||||
| Drug Name |
Hydromorphone prodrug
|
||||
| Synonyms |
PF-03 program; PF-329; Hydromorphone prodrug (Bio-MD/MPAR/oral, pain), PharmacoFore; Hydromorphone prodrug (Bio-MD, tamper/abuse-resistant, pain), PharmacoFore; Hydromorphone prodrug (Bio-MD/MPAR/oral/extended-release, pain); Hydromorphone prodrug (Bio-MD/MPAR/oral/extended-release, pain), PharmacoFore; Hydromorphone prodrug (tamper/abuse-resistant, Bio-MD/extended-release, Pain), PharmacoFore
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89] | Phase 1 | [1] | ||
| Company |
PharmacoFore Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H19NO3
|
||||
| Canonical SMILES |
CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4
|
||||
| InChI |
1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1
|
||||
| InChIKey |
WVLOADHCBXTIJK-YNHQPCIGSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9254, 81990, 7979546, 11039353, 14751077, 14873177, 39317885, 46508700, 48416092, 49993162, 50070721, 56394822, 57359121, 77568926, 96024740, 103557031, 104098728, 129640116, 134222944, 134337767, 134974682, 137005111, 139157539, 160963675, 175268533, 178103661, 179116727, 184536600, 198992261, 223798795, 226394766, 250134622, 252350812
|
||||
| Target and Pathway | |||||
| Target(s) | Mu-type opioid receptor | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Enkephalin release | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| Opioid Signalling | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034401) | ||||
| REF 2 | Clinical pipeline report, company report or official report of signaturerx. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.